Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), presents a formidable challenge in terms of targeted therapy due to its lack of specific molecular targets. Here, ERBB2 is linked to triple-negative breast carcinoma.